Impact BioMedical Inc. to Present at The Microcap Conference
Impact BioMedical Inc. (NYSE American: IBO) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO Frank D. Heuszel will deliver a corporate presentation on Wednesday, January 29, 2025, at 10:30 AM ET.
During the conference, Heuszel will conduct one-on-one meetings with investors to discuss the company's recent developments, growth strategy, and investment opportunities. Impact BioMedical, a biotechnology company, focuses on discovering, confirming, and patenting unique science and technologies for development into biopharmaceuticals and consumer healthcare solutions through various collaborative relationships including research, licensing, co-development, and joint ventures.
Impact BioMedical Inc. (NYSE American: IBO) ha annunciato la sua partecipazione a The Microcap Conference 2025, prevista per il 28-30 gennaio 2025, presso il Borgata Hotel Spa & Casino di Atlantic City, NJ. Il CEO Frank D. Heuszel presenterà l'azienda mercoledì 29 gennaio 2025, alle 10:30 AM ET.
Durante la conferenza, Heuszel terrà incontri individuali con gli investitori per discutere gli sviluppi recenti dell'azienda, la strategia di crescita e le opportunità di investimento. Impact BioMedical, un'azienda biotecnologica, si concentra sulla scoperta, conferma e registrazione di scienze e tecnologie uniche per lo sviluppo in farmaci biotecnologici e soluzioni per la salute dei consumatori attraverso varie relazioni collaborative, tra cui ricerca, licensing, co-sviluppo e joint ventures.
Impact BioMedical Inc. (NYSE American: IBO) ha anunciado su participación en The Microcap Conference 2025, programada para el 28-30 de enero de 2025, en el Borgata Hotel Spa & Casino en Atlantic City, NJ. El CEO Frank D. Heuszel realizará una presentación corporativa el miércoles 29 de enero de 2025, a las 10:30 AM ET.
Durante la conferencia, Heuszel mantendrá reuniones uno a uno con inversores para discutir los recientes desarrollos de la empresa, su estrategia de crecimiento y las oportunidades de inversión. Impact BioMedical, una empresa de biotecnología, se centra en descubrir, confirmar y patentar ciencias y tecnologías únicas para su desarrollo en biofármacos y soluciones de salud para el consumidor a través de diversas relaciones de colaboración, incluyendo investigación, licencias, co-desarrollo y empresas conjuntas.
임팩트 바이오메디컬 주식회사 (NYSE American: IBO)는 마이크로캡 컨퍼런스 2025에 참여할 예정이라고 발표했습니다. 이 행사는 2025년 1월 28일부터 30일까지 뉴저지 애틀랜틱 시티의 보르가타 호텔 스파 & 카지노에서 열립니다. CEO 프랭크 D. 하우젤은 2025년 1월 29일 수요일 오전 10:30(ET)에 기업 발표를 진행할 것입니다.
컨퍼런스 기간 동안 하우젤은 투자자들과 개별 미팅을 통해 회사의 최근 개발 사항, 성장 전략 및 투자 기회에 대해 논의할 예정입니다. 임팩트 바이오메디컬은 생명공학 회사로, 독특한 과학 및 기술을 발견하고 확인하며 특허를 받아 생물의약품 및 소비자 건강 솔루션으로 개발하기 위해 연구, 라이센싱, 공동 개발 및 조인트 벤처를 포함한 다양한 협력 관계를 활용합니다.
Impact BioMedical Inc. (NYSE American: IBO) a annoncé sa participation à The Microcap Conference 2025, prévue du 28 au 30 janvier 2025, au Borgata Hotel Spa & Casino à Atlantic City, NJ. Le PDG Frank D. Heuszel fera une présentation de l'entreprise le mercredi 29 janvier 2025, à 10h30 ET.
Au cours de la conférence, Heuszel rencontrera des investisseurs en tête-à-tête pour discuter des développements récents de l'entreprise, de sa stratégie de croissance et des opportunités d'investissement. Impact BioMedical, une entreprise de biotechnologie, se concentre sur la découverte, la validation et le brevetage de sciences et technologies uniques à développer en produits biopharmaceutiques et solutions de santé pour les consommateurs à travers diverses relations de collaboration, y compris la recherche, la licence, le co-développement et les coentreprises.
Impact BioMedical Inc. (NYSE American: IBO) hat seine Teilnahme an The Microcap Conference 2025 angekündigt, die vom 28. bis 30. Januar 2025 im Borgata Hotel Spa & Casino in Atlantic City, NJ, stattfinden wird. CEO Frank D. Heuszel wird am Mittwoch, den 29. Januar 2025, um 10:30 Uhr ET eine Unternehmenspräsentation halten.
Während der Konferenz wird Heuszel Einzelgespräche mit Investoren führen, um die aktuellen Entwicklungen des Unternehmens, die Wachstumsstrategie und Investitionsmöglichkeiten zu besprechen. Impact BioMedical, ein Biotechnologieunternehmen, konzentriert sich darauf, einzigartige wissenschaftliche und technologische Entdeckungen zu validieren und zu patentieren, um sie in biopharmazeutische Produkte und Verbraucher-Lösungen im Gesundheitsbereich zu entwickeln, durch verschiedene Kooperationen, einschließlich Forschung, Lizenzierung, Co-Entwicklung und Joint Ventures.
- None.
- None.
HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
Mr. Heuszel will deliver a corporate presentation and engage in one-on-one meetings with investors to discuss the company’s recent developments, growth strategy, and investment opportunities. Details regarding his presentation are below.
Impact BioMedical Inc. Microcap Conference Presentation
Date: Wednesday, January 29, 2025
Time: 10:30 AM ET
About Impact BioMedical, Inc.:
Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Investor Relations:
info@impactbiomedinc.com
FAQ
When is Impact BioMedical (IBO) presenting at The Microcap Conference 2025?
Where will The Microcap Conference 2025 featuring Impact BioMedical (IBO) be held?
What will be discussed during Impact BioMedical's (IBO) presentation at The Microcap Conference?
What is Impact BioMedical's (IBO) business focus according to their Microcap Conference announcement?
How can investors contact Impact BioMedical (IBO) for more information?
